A placebo-controlled exploratory study showed that exenatide treatment for 12 weeks did not affect cognitive function in women with IIH [28]
The appropriate choice depends on the patients BMI, health history, previous treatment response, goals, and long-term preferences
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
Additionally, the infusion of native human GIP (142) into cardiac myocytes isolated from embryonic mouse hearts inhibited the increase in brain natriuretic peptide (BNP) and transforming growth factor- (TGF- 1) mRNA expression induced by angiotensin II (Ang II) [13]
Its effects are more complex
July 12, 2022
